Neoadjuvant Cemiplimab for Resectable Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series
Head & Neck · 21.08.2026
DOI: 10.1002/hed.70438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, online erschienen am 21.08.2026. Verfasst von Whitney Jin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Introduction
A Phase II trial demonstrated that neoadjuvant cemiplimab was associated with pathologic complete response (pCR) in 51% of patients with locoregionally advanced cutaneous squamous cell carcinoma (cuSCC). We evaluated real‐world radiographic and pathologic responses to neoadjuvant cemiplimab and assessed radiologic–pathologic concordance.
Methods
Retrospective single‐institution cohort study including 18 patients with locoregionally advanced head and neck cuSCC treated with neoadjuvant cemiplimab before curative‐intent surgery between 2019 and 2024. Pathologic and radiographic responses were assessed using pathology review and RECIST 1.1/iRECIST. Results pCR occurred in 11 patients (61%) and major pathologic response (MPR) in 2 (11%), yielding a 72% combined pathologic response rate. Among 16 patients with evaluable imaging, only 33% demonstrated radiographic partial response (PR), and none achieved radiographic complete response. Radiologic response frequently underestimated tumor clearance.
Conclusions
Neoadjuvant cemiplimab produced high pathologic response rates in real‐world practice, while RECIST‐based imaging underestimated true tumor response, highlighting limitations of anatomic imaging in immunotherapy‐treated cuSCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Whitney Jin, Ryan K Rigsby, Austin Hoke, Robert Sinard, Kyle Mannion, Lindsay Mundy, Alexander Langerman, Barbara Murphy, Mitra Mehrad, Michael C Topf, Jennifer H Choe
Förderung
- NCI NIH HHS
Zitieren
APA
Jin, W., Rigsby, R. K., Ely, K., Hoke, A., Sinard, R., Mannion, K., Gilbert, J., Mundy, L., Langerman, A., Rohde, S., Murphy, B., Rosenthal, E., Mehrad, M., Topf, M. C., & Choe, J. H. (2026). Neoadjuvant Cemiplimab for Resectable Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series. Head & Neck. https://doi.org/10.1002/hed.70438
Vancouver
Jin W, Rigsby RK, Ely K, Hoke A, Sinard R, Mannion K, et al. Neoadjuvant Cemiplimab for Resectable Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series. Head & Neck. 2026. doi:10.1002/hed.70438
BibTeX
@article{Jin2026,
author = {Jin, Whitney and Rigsby, Ryan K and Ely, Kim and Hoke, Austin and Sinard, Robert and Mannion, Kyle and Gilbert, Jill and Mundy, Lindsay and Langerman, Alexander and Rohde, Sarah and Murphy, Barbara and Rosenthal, Eben and Mehrad, Mitra and Topf, Michael C and Choe, Jennifer H},
title = {Neoadjuvant Cemiplimab for Resectable Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70438}
}
EUVIMED